Print

Week in Review: Hutchison Medipharma Partners Cancer Drug With Eli Lilly and Company (LLY)  
10/14/2013 7:49:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

October 12, 2013 -- Hutchison MediPharma, a Chi-Med subsidiary, will partner its cancer drug fruquintinib with Lilly in a deal potentially worth $86.5 million; ASLAN Pharma of Singapore completed a Series B financing that brought in $22 million; Eddingpharm acquired China rights to Immutep’s ImmunFact IMP321, an immuno-treatment for breast cancer; Shenzhen Chipscreen Biosciences out-licensed Taiwanese rights for a cancer drug candidate to a Taiwanese startup; Sihuan Pharma received CFDA approval to begin clinical trials of pirotinib, an innovative cancer drug; a vaccine for Japanese encephalitis developed by China National Biotec was prequalified by the World Health Organization; Hutchison MediPharma will receive a $6 million milestone payment from Janssen Pharma in an inflammation drug partnership; two scientists formerly employed by Eli Lilly were indicted for passing proprietary information to an employee of Jiangsu Hengrui Medicine; and China police have arrested another suspect in the GlaxoSmithKline bribery case. More details….

Stock Symbol: (AIM: HCM) (NYSE: LLY) (HK: 0460) (NYSE: GSK)

Help employers find you! Check out all the jobs and post your resume.

//-->